Do analysts rate APLM or DTIL?

Precision BioSciences has a consensus price target of $32.25, suggesting a potential upside of 294.25%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Precision BioSciences 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has higher valuation & earnings, APLM or DTIL?

Apollomics has higher earnings, but lower revenue than Precision BioSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 5.06 -$10.94M N/A N/A Precision BioSciences $34.26M 6.16 -$45.72M -$3.67 N/A

Does the media favor APLM or DTIL?

In the previous week, Precision BioSciences had 2 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for Precision BioSciences and 1 mentions for Apollomics. Apollomics' average media sentiment score of 0.59 beat Precision BioSciences' score of 0.28 indicating that Apollomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend APLM or EQ?

Equillium has a consensus target price of $7.57, suggesting a potential upside of 160.19%. Given Equillium's stronger consensus rating and higher probable upside, analysts plainly believe Equillium is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Equillium 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Which has higher earnings and valuation, APLM or EQ?

Apollomics has higher earnings, but lower revenue than Equillium. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 5.06 -$10.94M N/A N/A Equillium $41.10M 4.48 -$22.40M -$0.32 N/A

Is APLM or EQ more profitable?

Apollomics' return on equity of 0.00% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Equillium N/A -61.43% -53.72%

Does the media favor APLM or EQ?

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Apollomics' average media sentiment score of 0.59 beat Equillium's score of 0.00 indicating that Apollomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend IPHA or APLM?

Innate Pharma currently has a consensus price target of $5.00, indicating a potential upside of 177.78%. Given Innate Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Innate Pharma is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, IPHA or APLM?

Apollomics has lower revenue, but higher earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 16.59 -$55.64M N/A N/A Apollomics $8.50M 5.06 -$10.94M N/A N/A

Is IPHA or APLM more profitable?

Company Net Margins Return on Equity Return on Assets Innate Pharma N/A N/A N/A Apollomics N/A N/A N/A

Does the media prefer IPHA or APLM?

In the previous week, Innate Pharma and Innate Pharma both had 1 articles in the media. Apollomics' average media sentiment score of 0.59 beat Innate Pharma's score of 0.00 indicating that Apollomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apollomics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate APLM or IMDX?

Oncocyte has a consensus price target of $12.00, indicating a potential upside of 109.06%. Given Oncocyte's stronger consensus rating and higher probable upside, analysts plainly believe Oncocyte is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Oncocyte 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, APLM or IMDX?

Apollomics has higher revenue and earnings than Oncocyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 5.06 -$10.94M N/A N/A Oncocyte $4.05M 45.76 -$50.22M -$1.48 N/A

Is APLM or IMDX more profitable?

Apollomics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Oncocyte -2,454.64% N/A -96.96%

Does the media favor APLM or IMDX?

In the previous week, Oncocyte had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Oncocyte and 1 mentions for Apollomics. Apollomics' average media sentiment score of 0.59 beat Oncocyte's score of 0.00 indicating that Apollomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate APLM or ACB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, APLM or ACB?

Apollomics has higher earnings, but lower revenue than Aurora Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 5.06 -$10.94M N/A N/A Aurora Cannabis $320.59M 0.54 -$88.13M -$1.56 N/A

Does the media favor APLM or ACB?

In the previous week, Aurora Cannabis had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Aurora Cannabis and 1 mentions for Apollomics. Aurora Cannabis' average media sentiment score of 0.66 beat Apollomics' score of 0.59 indicating that Aurora Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurora Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Apollomics (APLM) Competitors

$19.56 0.00 (0.00%)

Closing price 07/2/2026 03:59 PM Eastern

Extended Trading

$18.62 -0.94 (-4.81%)

As of 07/2/2026 06:01 PM Eastern

Compare

APLM vs. DTIL, EQ, IPHA, IMDX, and ACB

Should you buy Apollomics stock or one of its competitors? MarketBeat compares Apollomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apollomics include Precision BioSciences (DTIL), Equillium (EQ), Innate Pharma (IPHA), Oncocyte (IMDX), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry.

How does Apollomics compare to Precision BioSciences?

Apollomics (NASDAQ:APLM) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Apollomics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Apollomics' return on equity of 0.00% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Precision BioSciences	-96.73%	-85.37%	-37.34%

Precision BioSciences has a consensus price target of $32.25, suggesting a potential upside of 294.25%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Apollomics has higher earnings, but lower revenue than Precision BioSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A
Precision BioSciences	$34.26M	6.16	-$45.72M	-$3.67	N/A

In the previous week, Precision BioSciences had 2 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for Precision BioSciences and 1 mentions for Apollomics. Apollomics' average media sentiment score of 0.59 beat Precision BioSciences' score of 0.28 indicating that Apollomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precision BioSciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apollomics has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Summary

Precision BioSciences beats Apollomics on 8 of the 14 factors compared between the two stocks.

How does Apollomics compare to Equillium?

Apollomics (NASDAQ:APLM) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Apollomics' return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Equillium	N/A	-61.43%	-53.72%

Equillium has a consensus target price of $7.57, suggesting a potential upside of 160.19%. Given Equillium's stronger consensus rating and higher probable upside, analysts plainly believe Equillium is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Apollomics has higher earnings, but lower revenue than Equillium.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A
Equillium	$41.10M	4.48	-$22.40M	-$0.32	N/A

Apollomics has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Equillium has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Apollomics' average media sentiment score of 0.59 beat Equillium's score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.1% of Apollomics shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 17.8% of Equillium shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Equillium beats Apollomics on 8 of the 13 factors compared between the two stocks.

How does Apollomics compare to Innate Pharma?

Innate Pharma (NASDAQ:IPHA) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Innate Pharma has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Innate Pharma and Innate Pharma both had 1 articles in the media. Apollomics' average media sentiment score of 0.59 beat Innate Pharma's score of 0.00 indicating that Apollomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apollomics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apollomics has lower revenue, but higher earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.59	-$55.64M	N/A	N/A
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A

Innate Pharma currently has a consensus price target of $5.00, indicating a potential upside of 177.78%. Given Innate Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Innate Pharma is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Apollomics	N/A	N/A	N/A

Summary

Innate Pharma beats Apollomics on 7 of the 11 factors compared between the two stocks.

How does Apollomics compare to Oncocyte?

Apollomics (NASDAQ:APLM) and Oncocyte (NASDAQ:IMDX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

In the previous week, Oncocyte had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Oncocyte and 1 mentions for Apollomics. Apollomics' average media sentiment score of 0.59 beat Oncocyte's score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.1% of Apollomics shares are held by institutional investors. Comparatively, 55.4% of Oncocyte shares are held by institutional investors. 2.2% of Oncocyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Apollomics has higher revenue and earnings than Oncocyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A
Oncocyte	$4.05M	45.76	-$50.22M	-$1.48	N/A

Apollomics has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market.

Oncocyte has a consensus price target of $12.00, indicating a potential upside of 109.06%. Given Oncocyte's stronger consensus rating and higher probable upside, analysts plainly believe Oncocyte is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Apollomics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Oncocyte	-2,454.64%	N/A	-96.96%

Summary

Oncocyte beats Apollomics on 8 of the 13 factors compared between the two stocks.

How does Apollomics compare to Aurora Cannabis?

Apollomics (NASDAQ:APLM) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Apollomics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Apollomics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -33.57%. Aurora Cannabis' return on equity of 0.10% beat Apollomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Aurora Cannabis	-33.57%	0.10%	0.07%

Apollomics has higher earnings, but lower revenue than Aurora Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A
Aurora Cannabis	$320.59M	0.54	-$88.13M	-$1.56	N/A

In the previous week, Aurora Cannabis had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Aurora Cannabis and 1 mentions for Apollomics. Aurora Cannabis' average media sentiment score of 0.66 beat Apollomics' score of 0.59 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurora Cannabis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

19.1% of Apollomics shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Aurora Cannabis beats Apollomics on 9 of the 13 factors compared between the two stocks.

Get Apollomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLM vs. The Competition

Export

Metric	Apollomics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$42.96M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	N/A	21.61	28.02	24.70
Price / Sales	5.06	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-6.77	8.66	10.96	6.46
Net Income	-$10.94M	$23.81M	$3.57B	$337.01M
7 Day Performance	-5.96%	3.39%	2.12%	1.69%
1 Month Performance	37.26%	10.81%	5.25%	3.81%
1 Year Performance	200.69%	62.61%	33.29%	23.90%

Apollomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLM Apollomics	0.7489 of 5 stars	$19.56 flat	N/A	+200.7%	$42.96M	$8.50M	N/A	45
DTIL Precision BioSciences	2.5437 of 5 stars	$7.01 +0.8%	$32.25 +360.4%	+87.0%	$180.73M	$34.26M	N/A	200	News Coverage Gap Down
EQ Equillium	2.8469 of 5 stars	$2.79 -1.9%	$7.57 +171.9%	+789.9%	$178.31M	$41.10M	N/A	40	News Coverage
IPHA Innate Pharma	2.1212 of 5 stars	$1.90 +0.3%	$5.00 +163.9%	-1.2%	$177.88M	$10.19M	N/A	220	News Coverage
IMDX Oncocyte	2.5547 of 5 stars	$5.41 +0.7%	$12.00 +122.0%	N/A	$176.72M	$1.95M	N/A	120	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLM) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apollomics (APLM) Competitors

APLM vs. DTIL, EQ, IPHA, IMDX, and ACB

How does Apollomics compare to Precision BioSciences?

Summary

How does Apollomics compare to Equillium?

Summary

How does Apollomics compare to Innate Pharma?

Summary

How does Apollomics compare to Oncocyte?

Summary

How does Apollomics compare to Aurora Cannabis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apollomics (APLM) Competitors

APLM vs. DTIL, EQ, IPHA, IMDX, and ACB

How does Apollomics compare to Precision BioSciences?

Is APLM or DTIL more profitable?

Do analysts rate APLM or DTIL?

Do institutionals & insiders hold more shares of APLM or DTIL?

Which has higher valuation & earnings, APLM or DTIL?

Does the media favor APLM or DTIL?

Which has more volatility and risk, APLM or DTIL?

Summary

How does Apollomics compare to Equillium?

Is APLM or EQ more profitable?

Do analysts recommend APLM or EQ?

Which has higher earnings and valuation, APLM or EQ?

Which has more risk and volatility, APLM or EQ?

Does the media favor APLM or EQ?

Do insiders & institutionals have more ownership in APLM or EQ?

Summary

How does Apollomics compare to Innate Pharma?

Which has more risk & volatility, IPHA or APLM?

Do insiders and institutionals have more ownership in IPHA or APLM?

Does the media prefer IPHA or APLM?

Which has better valuation and earnings, IPHA or APLM?

Do analysts recommend IPHA or APLM?

Is IPHA or APLM more profitable?

Summary

How does Apollomics compare to Oncocyte?

Does the media favor APLM or IMDX?

Do insiders & institutionals believe in APLM or IMDX?

Which has stronger valuation & earnings, APLM or IMDX?

Which has more risk & volatility, APLM or IMDX?

Do analysts rate APLM or IMDX?

Is APLM or IMDX more profitable?

Summary

How does Apollomics compare to Aurora Cannabis?

Do analysts rate APLM or ACB?

Which has more risk and volatility, APLM or ACB?

Is APLM or ACB more profitable?

Which has better valuation & earnings, APLM or ACB?

Does the media favor APLM or ACB?

Do insiders and institutionals have more ownership in APLM or ACB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools